|Estimated screening-related resource use and health outcomes by year and screening scenario: biennial gFOBT at 55–74 years, biennial FIT at 55–74 years, and FSIG once at 60 years|
|Year of programme||Year 1||Year 10|
|Screening-related resource use|
|Screening tests||No. of kits sent out||357,812||357,812||420,151||417,464|
|No. of kits processed||189,640||189,640||222,637||220,999|
|No. of FSIG done1||18,617||20,625|
|COL/CTC||No. of diagnostic COL||967||11,095||381||1,103||12,414||423|
|No. of diagnostic CTC||126||1,442||50||143||1,614||55|
|No. of surveillance COL||0||0||0||297||2,406||620|
|No. of surveillance CTC||0||0||0||39||313||81|
|Pathology||No. of adenomas and CRCs requiring pathology2||1,004||7,161||1,599||1,356||8,909||2,222|
|CRC work-up and treatment||No. receiving PET scan||31||85||6||34||69||8|
|No. receiving MRI scan||111||307||23||121||247||28|
|No. receiving CT scan(s)||309||853||64||336||687||78|
|No. receiving TUS||16||43||3||17||35||4|
|No. receiving pre-operative radiotherapy3||71||196||15||75||146||17|
|No. undergoing colorectal resection4||281||779||59||307||635||71|
|Screening-related health outcomes|
|Harms5||No. with major bleeding following endoscopy||4||48||7||6||62||10|
|No. with perforation following endoscopy||2||21||1||2||27||2|
|No. of deaths from perforation following endoscopy||0||1||0||0||1||0|
|Screen-detected lesions||No. with adenoma(s)6||Total||366||3,320||808||537||4,327||1,128|
|No. with CRC7||Total||309||853||64||336||687||78|
COL colonoscopy, CRC colorectal cancer, CTC CT colonography, gFOBT guaiac-based faecal occult blood test, FIT faecal immunochemical test, FSIG flexible sigmoidoscopy, TUS ultrasound; intermediate/high-risk = adenoma(s) ≥10 mm; low-risk = adenoma(s) <10 mm;
1 includes FSIG with and without polypectomy.
2 sum of number of adenomas and colorectal cancers requiring pathology, assuming average of 1.9 adenomas per person; includes screen-detected and surveillance-detected adenomas.
3 applies to rectal cancer only; includes radiotherapy given with or without chemotherapy.
4 sum of estimates of colon and rectal resections required.
5 includes complications from diagnostic and surveillance endoscopy, including FSIG where relevant.
6 includes individuals with screen-detected and surveillance-detected adenomas.
7 includes individuals with CRC detected at screening and at surveillance.
Sharp et al.
Sharp et al. BMC Health Services Research 2013 13:105 doi:10.1186/1472-6963-13-105